TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SanBio Co ( (JP:4592) ) has provided an announcement.
SanBio Co., Ltd. announced that its application for a partial change in marketing approval for AKUUGO Suspension for Intracranial Implantation will be reviewed by regulatory authorities, with a decision expected by January 2026. The outcome of this review is anticipated to have minimal financial impact for the current fiscal year, but it could enhance SanBio’s position in the regenerative medicine market by potentially expanding the use of its stem cell-based product for brain injury treatment.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001 and headquartered in Tokyo, Japan, is a leader in regenerative medicine. The company focuses on the research, development, manufacture, and sale of regenerative cell medicines, particularly targeting central nervous system disorders with unmet medical needs.
Average Trading Volume: 2,274,127
Technical Sentiment Signal: Buy
Current Market Cap: Yen175.1B
See more data about 4592 stock on TipRanks’ Stock Analysis page.